Why Should Hydrocodone Combination Products Be Categorized as CII Drugs?

Published Online: Thursday, January 30, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, explains why hydrocodone combination products should no longer be categorized as Schedule III drugs.
 
This is the eleventh in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
A former pharmacy technician thought the prescription pill records she was finagling were better shred than read.
A Maryland pharmacist has been charged with the theft of more than 7300 tablets of hydrocodone, a painkiller found in Vicodin and Lortab.
The FDA today approved hydrocodone bitartrate, an extended-release opioid analgesic for treating severe pain that requires daily long-term opioid treatment and for which other treatment options are inadequate.
A diverse collective of health care advocacy groups, patient organizations, industry representatives and other stakeholders today announced they have established the Alliance for Balanced Pain Management to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse. AfBPM will work collaboratively to educate, support and advocate on behalf of people affected by pain, both acute and chronic.
Latest Issues
$auto_registration$